ARGX Stock Summary and Trading Ideas (Argenx Se - American Depositary Shares | NASDAQ:ARGX)

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Argenx Se - American Depositary Shares trades on the NASDAQ stock market under the symbol ARGX.

As of October 23, 2026, ARGX stock price declined to $873.71 with 284,264 million shares trading.

ARGX has a beta of 0.16, meaning it tends to be less sensitive to market movements. ARGX has a correlation of 0.00 to the broad based SPY ETF.

ARGX has a market cap of $54.94 billion. This is considered a Large Cap stock.

Last quarter Argenx Se - American Depositary Shares reported $2 billion in Revenue and $7.80 earnings per share. This beat revenue expectation by $112 million and exceeded earnings estimates by $28.58.

In the last 3 years, ARGX traded as high as $1,072.75 and as low as $327.73.

The top ETF exchange traded funds that ARGX belongs to (by Net Assets): IBB, CGGO, FBT, FENI, AVDE.

ARGX has underperformed the market in the last year with a return of +7.6%, while the SPY ETF gained +14.3%. In the last 3 month period, ARGX fell short of the market, returning -5.5%, while SPY returned +3.2%. However, in the most recent 2 weeks ARGX has outperformed the stock market by returning +5.9%, while SPY returned -2.4%.

ARGX support price is $855.96 and resistance is $895.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARGX shares will trade within this expected range on the day.